Cannabidiol (CBD) is a cannabinoid found in Cannabis. It is a major constituent of the plant, representing up to 40% in its extracts. It is the product of Cannabidiolic Acid (CBD-A) which convert to CBD when burned, vaporized, or exposed to certain teperatures for c'ertain tim'e p'eriods.
It has displayed sedative effects in animal tests. Some research, however, indicates that CBD can increase alertness. It may decrease the rate of THC clearance from the body, perhaps by interfering with the metabolism of THC in the liver.
Medically, it has been shown to have Anti-Oxidant, Analgestic, Anti-Bacterial, Anti-Diabetic, Anti-emetic, Anti-epileptic, Anti-Ischemic, Anti-Imflammitory, Anti-Psychotic, Anti-Spasmodic, Anxiolitic, Bone Stimulant, Immunosuppresive, Intestinal Anti-Prokinetic, Neurp-protective, Anti-Psoriadic, and Anti-Proliferative properties. It is thought to be one of the, if not the most medicinally valuabl'e compund found in Cannabis. Its Analgesic, Anti-spasmodic, Anti-Proliferative or Anti-cancer properties have been shown to be more than that of THC. Similar to THC-A, CBD-A has been shown to hold much of the Anti-imflammitory, Anti-Proiferative, and Anti Spasmodic potential of CBD and Cannabis
A 2008 study published in the British Journal of Psychiatry showed significant differences in Oxford-Liverpool Inventory of Feelings and Experiences scores between three groups: The first consisted of non-cannabis users, the second consisted of users with Δ9-THC detected, and the third consisted of users with both Δ9-THC and CBD detected. The Δ9-THC only group scored significantly higher for unusual experiences than the Δ9-THC and CBD group, whereas the Δ9-THC and CBD group had significantly lower introvertive anhedonia scores than the Δ9-THC only group and non-cannabis user group. This research indicates that CBD acts as an anti-psychotic and may counteract the potential effects of THC on individuals with latent schizophrenia.